Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Kazakhstan and Georgia could be future clinical trial hubs

By Brian Buntz | November 8, 2022

Clinical trial trends were on display

[Image courtesy of iStock Photo]

Pharma and biotech companies looking to perform clinical trials in Eastern Asia and Central Asia may want to consider alternatives as the Russia–Ukraine War continues.

Georgia and Kazakhstan, for instance, could be new venues for life science companies looking to conduct clinical trials. 

Russia and Ukraine both had strong clinical trial growth before 2022

Before the war’s disruption, Russia and Ukraine emerged as popular clinical trial sites. But the ongoing war in Ukraine has led to significant sanctions against Russia and logistical troubles.

“It has had a great impact on clinical trials,” said Andrey Tarakanov, CEO of the clinical trial logistics firm COREX Logistics . In addition to its Dublin, Ireland headquarters, COREX has locations in Kazakhstan, Georgia, Ukraine, Armenia, Russia and Belarus.  

The number of clinical trials in Russia has skyrocketed in recent years from 71 in 2017 to 797 in 2021, according to GlobalData. In Ukraine, there were almost 400 clinical trials in April. That figure, however, has since fallen to 287, according to ClinicalTrials.gov. 

Russia, in particular, has a good regulatory track record for clinical trials. According to data gathered by COREX before Russia’s invasion of Ukraine, FDA inspectors determined there was no action indicated (NAI) for 73.60% of Russian clinical trials. For U.S.-based clinical trials, 52.17% reached the same benchmark.

data from FDA audits

[Image courtesy of COREX Logistics]

While Russia’s annexation of the Crimean peninsula from Ukraine in 2014 also impacted clinical trials, it was temporary.

“Some companies postponed their clinical trial activities, but they did not quit them,” Tarakanov said.

By 2015 or 2016, clinical trial activities in the area stabilized.    

Why Kazakhstan and Georgia have clinical trial promise

Before Russia invaded Ukraine on Feb. 24, 2022, roughly 3% of the world’s clinical trials were based in either country. A large portion of those focused on treating oncological, hematological and neurological diseases. 

Dr. Andrey Tarakanov

Dr. Andrey Tarakanov

But the Russia–Ukraine War is likely to persist for months or years, causing further clinical research disarray.

“I expect a decrease in clinical trials in Russia and Ukraine in the near future,” Tarakanov said. 

Several countries near Russia or Ukraine — mostly with relatively little clinical trial expertise — could help fill the gap. Tarakanov floated a list of potential candidates, including Kazakhstan, Georgia, Tajikistan, Romania and Azerbaijan.  

Georgia increased its presence in the clinical trials arena when Mikheil Saakashvili was the country’s president from 2008 to 2013. As a result, the government began to work toward establishing a robust clinical trial infrastructure. It has a strong medical system with highly trained physicians and experience with laboratory studies, including for pediatrics. Georgia also has swift clinical trial authorization timelines.

“Depending on the culture, it can take three, four or six months for approval,” Tarakanov said. “In Georgia, it usually takes only one month.” 

Kazakhstan is also a burgeoning country for clinical trials. Industry giants ranging from AbbVie to IQVIA to Sanofi have a presence in the country. 

The country’s research, academic and medical organizations have lent their support to clinical trials. Kazakhstan also invests in medical technology, increasing its health care budget by 16% between 2021 and 2022. 

Many clinics in the country are private, offering autonomy in decision-making and giving sponsors freedom in selecting sites for clinical studies 

Kazakhstan also has an advantage for Russian-speaking clinical trial experts. “Kazakhstan is very similar to Russia in terms of logical infrastructure,” Tarakanov said. 

Kazakhstan also counts Russian as an official language next to Kazakh. “Doctors there write Medical documents in Russian,” Tarakanov said. 

Russian clinical trial researchers looking to emigrate will also likely find it easier to relocate to Kazakhstan — or Georgia — than to Western Europe or the U.S. 


Filed Under: clinical trials, Drug Discovery
Tagged With: Corex, Georgia, Kazakhstan
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Zoliflodacin wins FDA nod for treatment of gonorrhea
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE